Marksans Pharma Limited updates on USFDA inspection at Verna, Goa manufacturing facility

Marksans Pharma Limited has announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company located in Vema, Goa, India from 9th April 2024 to 17th April 2024.

On conclusion of the inspection, the Company has received 5 inspectional observations inForm 483. There is no data integrity observation. The Company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 174.40 as compared to the previous close of Rs. 170.60. The total number of shares traded during the day was 564556 in over 5763 trades.

The stock hit an intraday high of Rs. 178.75 and intraday low of 165.50. The net turnover during the day was Rs. 97691061.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 USFDA Inspection Verna Goa ManufacturingFacility